Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.
Findings, presented at the 2018 AACR Annual Meeting, demonstrated that an off-the-shelf, dual-targeted chimeric antigen receptor (CAR) T-cell approach found positive results in preclinical specificity, functionality, and efficacy studies.
According to the results from a phase I study, BLU-667, a next-generation tyrosine kinase inhibitor, was well-tolerated and demonstrated clinical benefit in patients with advanced, <em>RET</em>-altered solid tumors who had progressed on previous therapies. These findings were presented April 14 to 18 at the ASCR Annual Meeting 2018 in Chicago, Illinois.
According to data from a randomized phase III trial presented at the 2017 San Antonio Breast Cancer Symposium, a mix of traditional and customized acupuncture techniques were effective in reducing pain and stiffness associated with aromatase inhibitor therapy in women with early-stage breast cancer.
A novel approach to treatment for patients with smoldering multiple myeloma demonstrated a high rate of complete responses, according to a study presented at the 2017 ASH Annual Meeting. The single-arm, phase II trial evaluated a strategy using induction therapy with carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone followed by high-dose therapy and autologous stem cell transplantation, consolidation therapy and then maintenance therapy with lenalidomide and dexamethasone.
The combination of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) demonstrated promising clinical activity in patients with relapsed/refractory Hodgkin lymphoma, according to results from a phase I/II trial presented at the 2017 ASH Annual Meeting.
Treatment using BLU-285 (Avapritinib) induced clinically significant activity in patients with an advanced or aggressive form of systemic mastocytosis (ASM), a rare blood disorder that originates in mast cells, according to data from an ongoing phase I trial.<br />
Incidence of venous thromboembolism (VTE) recurrence was reduced in patients with cancer with oral rivaroxaban (Xarelto) therapy compared with dalteparin (Fragmin), the current standard of care, according to results from the Select-D pilot trial presented during the 2017 ASH Annual Meeting and Exposition.
Early-stage breast cancer recurrence and mortality was reduced by shortening the intervals between chemotherapy cycles or administering the drugs sequentially compared with standard dosing techniques, according to meta-analysis results presented at the 2017 San Antonio Breast Cancer Symposium.